WO2011142530A2 - 피부 충전제 조성물 - Google Patents
피부 충전제 조성물 Download PDFInfo
- Publication number
- WO2011142530A2 WO2011142530A2 PCT/KR2011/001556 KR2011001556W WO2011142530A2 WO 2011142530 A2 WO2011142530 A2 WO 2011142530A2 KR 2011001556 W KR2011001556 W KR 2011001556W WO 2011142530 A2 WO2011142530 A2 WO 2011142530A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dextran
- solution
- skin
- sodium chloride
- composition
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Definitions
- the present invention relates to a composition of a new dermal filler and a method for producing the same, which can be injected into the body via injection to give any form quickly.
- Soft tissues of the human body are maintained by extracellular matrix including proteins such as collagen and elastin and glycosaminoglycans, and soft tissues caused by congenital factors or external shocks or pathological factors.
- a defect occurs, the shape has been restored and corrected by inserting biological tissue or synthetic polymer chemical into the region to expand the soft tissue.
- a substance similar to skin tissue is injected into a specific area by injection to expand the soft tissue, and thus a substance used for wrinkle improvement or contour correction is generally called a dermal filler or filler.
- a dermal filler Depending on the mechanism of action that produces an effect, it can be classified into two types as follows.
- One is a dermal filler in which the injected substance increases the volume directly and gives an enlargement effect.
- the other is a volume effect by forming new collagen-like tissues around the skin by stimulation of the substance in addition to the direct volume effect of the injected substance.
- Skin fillers can also be classified into three types, depending on the duration of effect:
- a skin filler that decomposes and absorbs quickly within one year and secondly, a skin filler that decomposes and absorbs within a year is longer than a dermal filler that decomposes and absorbs quickly within one year. It is divided into skin fillers that stay with.
- Collagen and hyaluronic acid which are the main ingredients of current skin fillers, are the skin fillers that are rapidly decomposed and absorbed within a year while increasing the volume directly to increase the volume.
- Polyacrylamide Ingredients are skin fillers that do not disintegrate in vivo while staying intact and expand in volume, and polymethylmethacrylate (PMMA) is a substance that is stimulated by the stimulation of the material in addition to the direct volume effect of the injected material. It forms a new collagen-like autologous tissue around the skin, which is a non-decomposable, permanently retaining dermal filler.
- cross-linked dextran can be used to stimulate the substance. New tissues like collagen Throwing the volume effects by sex, decomposing period corresponds to a skin filler that is eventually degraded and absorbed long, but compared to skin fillers are decomposed quickly absorbed within the year.
- Preferred dermal fillers are required to have several conditions: First, the biocompatibility should be excellent and safe. Second, the cost is low and the burden on the use is practically low. Third, the volume effect of the graft site should be maintained for a long time for more than two years.
- collagen-based skin fillers include EVOLENCE 30 (trade name of ColBar LifeScience skin filler), porcine collagen, Zyderm or Zyplast (above, Inamed skin filler), human collagen CosmoDerm and CosmoPlast (trade name of skin fillers of Inamed Co., Ltd.) are known as the main ingredient.
- the main ingredients of hyaluronic acid are Rofilan (trade name of skin filler of Rofil / Philoderm), Perlane, Restylane (trade name of dermal filler of Medicis / Q-Med AB company), Teosyal (dermal filler of Teoxane SA company) Trade name), Surgiderm (trade name of Corneal Laboratoire dermatological fillers), and the like.
- Rofilan trade name of skin filler of Rofil / Philoderm
- Perlane trade name of dermal filler of Medicis / Q-Med AB company
- Teosyal dermal filler of Teoxane SA company
- Surgiderm trade name of Corneal Laboratoire dermatological fillers
- Hyaluronic acid which is used for injectable dermal fillers, is an artificially synthesized product. use. In terms of duration, hyaluronic acid eventually disintegrates and disappears within one year, and crosslinked dextran lasts for one to two years, which is longer than that, and eventually all disintegrates. Nevertheless, the effect lasts longer due to the formation of new tissue such as collagen.
- hyaluronic acid (hyaluronic acid) component of the majority of the product has a problem that the filler is quite expensive.
- a longer-lasting product than the above-mentioned dermal filler containing cross-linked dextran is Artefill (trade name of Artes Medical's dermal filler) based on polymethyl methacrylate (PMMA) and collagen.
- Artefill trade name of Artes Medical's dermal filler
- PMMA polymethyl methacrylate
- PMMA polymethyl methacrylate
- the collagen used is derived from animals as a bovine extract, pretreatment such as an allergic skin test is necessary before use, which is a major obstacle in actual clinical application.
- the collagen component is very expensive, the economic burden on the patient is high, and the collagen component, which takes up most of the product volume, is decomposed and absorbed too quickly in the human body when injected (newly absorbed in 3 to 6 weeks).
- the collagen component which takes up most of the product volume, is decomposed and absorbed too quickly in the human body when injected (newly absorbed in 3 to 6 weeks).
- PMMA polymethyl methacrylate
- U.S. Patent US 2003/0233150 also discloses compositions for repairing or expanding body tissues comprising polymethylmethacrylate (PMMA) as the base polymer and dextran as a carrier.
- PMMA polymethylmethacrylate
- the US patent US 2003/0233150 is a polymethyl methacrylate (PMMA) component is not permanently degraded in vivo, there is a possibility that side effects occur.
- cross-linked dextran induces autologous collagen formation by inducing a foreign body reaction for a certain period of time without being fed by macrophages, as well as directly increasing volume when injected into tissue.
- Patent No. 10-0759091 based on polymethyl methacrylate (PMMA) and cross-linked dextran has been introduced to solve some of the problems of conventional skin fillers as described above. Improving.
- composition does not require pretreatment such as allergic reaction test before the procedure, and it is inexpensive and does not dissolve and absorb easily in the body, so the effect lasts for a long time.
- pretreatment such as allergic reaction test
- the composition is suitable for enlarged injection penis because it feels a little hard when injected under the skin, but has a disadvantage of being unsuitable for use in a wide range of other parts of the human body, including the face that requires a softer touch.
- the bead size in the dried state is 40 to 120 ⁇ m, when hydrated in 0.15M sodium chloride aqueous solution, the diameter of the median of the bead size (bead size) is 127 ⁇ m, the diameter of the hydrated / dried state As the ratio is 1.83 (6.1 by volume ratio), the effect of volume expansion is very insignificant, and it is difficult to inject without a carrier, so a carrier having a volume effect such as collagen or hyaluronic acid is required. This was because it felt very hard due to the rigid capsule formed by the reaction (see FIG. 2), thus conventional crosslinking.
- Dextran was not suitable to be the main single component of the filler due to the difficulty of infusion when used alone and the firm touch on the injection site.It can be used by adding a substance such as collagen or hyaluronic acid as a carrier and main ingredient. There was only a problem.
- the present invention is to solve the problems of the conventional skin fillers as described above, even when the cross-linked dextran having a molecular weight of 30,000 or more and 100,000 or less alone as the main component of the skin filler, easy to inject and soft touch of the injection site It is to be maintained.
- the present invention does not contain collagen or hyaluronic acid, unlike the conventional dermal filler containing collagen or hyaluronic acid as a main component, and does not require pretreatment such as allergic reaction test before the procedure, and dextran It is inexpensive and is not easily decomposed and absorbed by collagen or hyaluronic acid in the body, so the volumetric effect of the procedure can be maintained more stably for longer periods than collagen or hyaluronic acid. It is suitable for use in surgery such as injection penis enlargement, and it does not contain polymethyl methacrylate (PMMA) unlike the conventional dermal filler whose main ingredient is dextran cross-linked with polymethyl methacrylate (PMMA).
- PMMA polymethyl methacrylate
- the present invention relates to a composition of a new dermal filler, which is injected into the body through injection to give an arbitrary form quickly and maintains a soft touch.
- a dermal filler composition comprising tran, an aqueous sodium chloride solution and a viscosity modifier, but not including polymethylmethacrylate (PMMA).
- PMMA polymethylmethacrylate
- the present invention also includes an aqueous solution of sodium chloride, which is an isotonic solution of 0.3 to 0.4 g of cross-linked dextran having a molecular weight of 30,000 or more and a molecular weight of less than 30,000 or more per 100,000 ml of skin filler composition, pH 6 to pH 8 [polymethylmethacrylate] (PMMA) except that] to provide a dermal filler composition.
- the viscosity modifier is hydroxypropyl methyl cellulose (HPMC), 0.02 to 0.06 g is used.
- the present invention also includes an aqueous solution of sodium chloride which is 0.3 to 0.4 g of cross-linked dextran having a molecular weight of 30,000 or more and 100,000 or less per 10 ml of a skin filler composition, pH 6 to pH 8, and a viscosity modifier [polymethyl methacrylate (PMMA); It is to provide a dermal filler composition, characterized in that.
- a viscosity modifier is hydroxypropyl methyl cellulose (HPMC) is used 0.02 ⁇ 0.06g.
- the present invention relates to a method for preparing a skin filler composition, the molecular weight of more than 30,000 or more cross-linked dextran 0.3 ⁇ 0.4g in physiological saline (0.9% sodium chloride aqueous solution) to continuously wash the solution of dextran space Fitting to an isotonic solution; Adjusting the pH of the aqueous sodium chloride solution adjusted to the isotonic solution to pH6 ⁇ pH8; It is to provide a method for preparing a skin filler composition comprising the step of adding a viscosity modifier. In this case, it is preferable to perform cytotoxicity removal in preparation for the presence of impurities in the crosslinked dextran.
- cross-linked dextran having a molecular weight of 30,000 or more and 100,000 or less is hydrated in distilled water, sterilized under high temperature and high pressure for a predetermined time, and then into the cross-linked dextran hydrate.
- a skin filler composition is prepared by adding a viscosity modifier.
- the present invention is composed of a high-molecular material, not a material extracted from the animal, the production process is simple, there is an effect that the manufacturing cost is much lower bar that does not use expensive collagen.
- crosslinked dextran which has a molecular weight of 30,000 or more and less than 100,000, and has been treated with cytotoxicity as a main component of the skin filler, is the first case that has not been seen in conventional skin fillers, and it is easy to inject and inject the skin filler. It has the effect of maintaining a softer touch.
- 1 is a vial picture containing the skin filler of the present invention.
- FIG. 2 shows the content of crosslinked dextran having a molecular weight of 30,000 or less (product name: DEAE Sephadex 25), which was incidentally used in all conventional skin filler compositions, and the content of crosslinked dextran of 100,000 or more and less than 100,000 of the skin filler composition of the present invention.
- the cross-linked dextran having a molecular weight of 30,000 or more and 100,000 or less which is a main component of the dermal filler composition of the present invention, is a microprototype having a bead size of 40 to 120 ⁇ m in a dried state, and immediately increases in volume when injected into the tissue. At the same time, it does not phagocytosis by macrophages, it causes a foreign body reaction in the body for a certain period of time to induce autologous collagen formation to maintain a continuous volumetric effect.
- crosslinked dextran used as incidental in all conventional skin fillers has a molecular weight of 30,000 or less (product name: DEAE Sephadex 25).
- the dried bead size is the same as the crosslinked dextran of 100,000 or less of 30,000 or more of the present invention, but when hydrated in 0.15M aqueous sodium chloride solution, the median diameter of the bead size is 127 ⁇ m.
- the diameter ratio of hydrated / dry state is 1.83 (6.1 when converted to volume ratio), and the volume expansion effect is insignificant, and it is difficult to inject without a carrier, so a carrier having a volume effect such as hyaluronic acid is required. This is because the feel of the injection site felt very hard due to the formation of a rigid capsule due to tissue reaction.
- the cross-linked dextran having a molecular weight of 30,000 or more and less than 100,000 of the present invention has a diameter of 214 ⁇ m when the diameter of the bead size is 214 ⁇ m when hydrated in a 0.15 M aqueous sodium chloride solution, and the diameter ratio of the hydrated / dry state is It is 3.17 (which is 31.8 in terms of volume ratio), and has a very good volume expansion effect, and it is easy to inject by itself, so it does not require a carrier such as collagen or hyaluronic acid, and has a soft touch feel.
- Figure 1 is a vial photograph containing the skin filler of the present invention
- Figure 2 is a cross-linking molecular weight of 30,000 or less (product name: DEAE Sephadex 25) used incidentally in all conventional skin filler compositions
- a vial when hydrated dextran is hydrated in saline solution (0.9% aqueous sodium chloride solution) at a content equal to or greater than 30,000 or more and less than 100,000 crosslinked dextran content of the dermal filler composition of the present invention used in conventional skin filler compositions
- the molecular weight of the present invention can be confirmed that the volumetric effect of the crosslinked dextran having a molecular weight of 30,000 or more is less than 100,000.
- the carrier composition had to be added with a carrier having a volume effect such as collagen or hyaluronic acid, but the molecular weight was 30,000 or more as in the present invention.
- the present invention does not contain collagen or hyaluronic acid, it does not require pretreatment such as an allergic reaction test before the procedure, and it is inexpensive, and it is not easily decomposed and absorbed by the body, thereby increasing the volumetric effect by the procedure for a long time Since it can be stably maintained, it is suitable for use in surgery such as enlarged injection penis which requires the injection of a large amount of skin filler over 20cc.
- the impurity may be included in the preparation of crosslinked dextran in the skin filler composition of the present invention, it is preferable to further include a cytotoxicity removal step, the cytotoxicity removal step is molecular weight in the cross-linked dextran distilled water At least 30,000 or more of the crosslinked dextran of 100,000 or less is hydrated, sterilized under a high temperature and a high pressure for a certain time, and then distilled water which is not absorbed into the crosslinked dextran hydrate is removed, and an aqueous sodium chloride solution is added to the crosslinked dextran. It is made through the process of dissolving the toxins inside. In this case, in order to reduce the volume of the dextran particles more effectively, it is preferable to use a high concentration of aqueous sodium chloride solution of 0.9% or more.
- the dermal filler composition of the present invention uses only the cytotoxicly-removed crosslinked dextran as a main ingredient alone, without harming the human body, and the manufacturing process is simpler and more practical to use.
- the touch is soft and very soft, so it can be used not only on the skin of the penis but also on the skin of a wide range of other parts of the body including the face.
- the crosslinked dextran having a molecular weight of 30,000 or more and 100,000 or less preferably uses 0.3 to 0.4 g per 10 ml of the dermal filler composition. If less than 0.3g is used, excess moisture is too much, so it is easily absorbed in the body by the amount of excess moisture, which does not maintain the volume expansion effect by the procedure for a longer period of time. In order to maintain the bulking effect stably for a long time and to maintain the soft feel of the injection site, the crosslinked dextran having a molecular weight of 30,000 or more and 100,000 or less per 100,000 ml is required in order to maintain the volume expansion effect for a long time and to maintain a soft touch. Preference is given to using 0.4 g.
- the aqueous sodium chloride solution is preferably an isotonic solution having a pH of 6 to pH 8 so that the skin filler is suitable for infusion into the body .
- the viscosity modifier in the present invention serves to facilitate the injection of the dermal filler by maintaining the cross-linked dextran gel (gel) state.
- hydroxypropyl methylcellulose, sodium carboxymethylcellulose, chitosan, polyethylene glycol, PEG, polylactic glycolamide (PLGA), polyvinyl alcohol (polyvinyl alcohol) PVA), dextran, hyaluronic acid, or cross-linked hyaluronic acid, and the like may be used alternatively.
- Hydroxypropyl methyl cellulose (HPMC) in the viscosity modifier is preferably to include 0.02 ⁇ 0.06 g per 10 ml of the skin filler composition.
- the present invention relates to a method for preparing a skin filler composition, the molecular weight of more than 30,000 or more cross-linked dextran 0.3 ⁇ 0.4g in physiological saline (0.9% sodium chloride aqueous solution) to continuously wash the solution of dextran space Fitting to an isotonic solution; Adjusting the pH of the aqueous sodium chloride solution adjusted to the isotonic solution to pH6 ⁇ pH8; It relates to a method for preparing a skin filler composition comprising the step of adding a viscosity modifier. In this case, it is preferable to perform cytotoxicity removal in preparation for the presence of impurities in the crosslinked dextran.
- crosslinked dextran having a molecular weight of 30,000 or more and 100,000 or less in the distilled water is hydrated, sterilized under a high temperature and high pressure for a certain time, and then crosslinked dextran hydrate.
- Cytotoxicity removal step of the cross-linked dextran is first hydrated by 0.3 ⁇ 0.4g of cross-linked dextran having a molecular weight of 30,000 or more in 100,000 or more in distilled water so that the cross-linked dextran is largely absorbed by water to expand. Sterilize under high temperature and high pressure.
- the distilled water not absorbed into the crosslinked dextran hydrate is removed, and an aqueous sodium chloride solution is added thereto.
- the water inside the crosslinked dextran particles is discharged to the aqueous sodium chloride solution outside the dextran particles due to osmotic pressure.
- the volume of is reduced, and in this process, the toxins inside the crosslinked dextran are eluted together to remove the toxicity.
- the step of adjusting the aqueous solution of sodium chloride between the cross-linked dextran hydrate particles is an isotonic solution, the aqueous solution of sodium chloride between the cross-linked dextran particles subjected to the cytotoxicity of the cross-linked dextran, the cross-linked dextran due to osmotic pressure
- the sodium concentration per unit volume of the aqueous sodium chloride solution between the crosslinked dextran particles decreases (or if the cross-linked dextran removal step
- a high concentration of aqueous solution of sodium chloride of 0.9% or more is used, the water inside the crosslinked dextran particles is discharged to the aqueous solution of sodium chloride outside the dextran particles due to osmotic pressure, so that the solution of the crosslinked dextran space is somewhat diluted compared to the isotonic solution.
- Is still sodium The concentration may be high), so that the aqueous solution of sodium chloride is continuously washed with physiological saline (0.9% aqueous sodium chloride solution) to adjust the solution to the isotonic solution so that the crosslinked solution of dextran and the aqueous solution of sodium chloride are isotonic solution.
- the step of adding a viscosity modifier is a step of adding a viscosity modifier to facilitate the injection of dermal fillers by maintaining the gel state of the cross-linked dextran hydrate is adjusted to a pH, In the case of hydroxypropyl methylcellulose (HPMC), it is preferred to add 0.02 to 0.06 g per 10 ml of said pH-adjusted dermal filler.
- HPMC hydroxypropyl methylcellulose
- a dermal filler containing only inexpensive crosslinked dextran as a main ingredient such as the dermal filler composition according to the present invention
- it is possible to easily inject the dermal filler under the dermis through injection to maintain rapid enlargement of the applied area and a soft touch.
- it does not contain collagen or hyaluronic acid, so it does not require pretreatment such as allergic reaction test before the procedure, and it is inexpensive, and it is not easily decomposed and absorbed by the body.
- the effect can be stable for longer periods of time, making it suitable for use in surgeries such as penis enlargement, which requires the injection of large amounts of dermal fillers of 20 cc or more.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Description
Claims (6)
- 분자량이 30,000 이상의 100,000 이하인 가교된 덱스트란;염화나트륨 수용액; 및점도조절제를 포함[폴리메틸메타크릴레이트(PMMA)를 포함하는 것을 제외한다]하는 피부 충전제 조성물.
- 증류수에 분자량이 30,000 이상의 100,000 이하의 가교된 덱스트란을 넣어 수화시키고, 일정 시간 고온, 고압 하에서 멸균 처리한 후, 가교된 덱스트란 수화물 내부로 흡수되지 아니한 증류수를 제거하고, 이에 염화나트륨 수용액을 넣어 가교된 덱스트란 내부의 독소가 용출되도록 하는 과정을 통해 세포독성 제거 처리한 가교된 덱스트란;염화나트륨 수용액; 및점도조절제를 포함(폴리메틸메타크릴레이트(PMMA)를 포함하는 것을 제외한다)하는 피부 충전제 조성물.
- 제1항 또는 제2항에 있어서, 염화나트륨 수용액은 pH6~pH8인 등장액인 것을 특징으로 하는 피부 충전제 조성물.
- 피부 충전제 조성물 10 ㎖당 분자량이 30,000 이상의 100,000 이하의 가교된 덱스트란 0.3~0.4g;pH6~pH8의 등장액인 염화나트륨 수용액; 및점도조절제인 하이드록시프로필 메틸셀룰로오즈(HPMC) 0.02~0.06g을 포함하는 것을 특징으로 하는 피부 충전제 조성물.
- 분자량이 30,000 이상의 100,000 이하의 가교된 덱스트란 0.3~0.4g에 생리식염수(0.9% 염화나트륨 수용액)을 넣고 지속적으로 세척하여 덱스트란 외부공간의 용액이 등장액이 되도록 맞추는 단계;등장액으로 맞춰진 염화나트륨 수용액의 pH를 pH6~pH8로 맞추는 단계; 및점도조절제를 첨가하는 단계를 포함하는 피부 충전제 조성물 제조방법.
- 증류수에 분자량이 30,000 이상의 100,000 이하의 가교된 덱스트란 0.3~0.4g을 넣어 수화시키고, 일정 시간 고온, 고압 하에서 멸균 처리한 후, 가교된 덱스트란 수화물 내부로 흡수되지 아니한 증류수를 제거하고, 이에 염화나트륨 수용액을 넣어 가교된 덱스트란 내부의 독소가 용출되도록 하는 가교된 덱스트란의 세포독성 제거처리단계;상기 세포독성제거처리된 가교된 덱스트란에 생리식염수(0.9% 염화나트륨 수용액)를 넣고 지속적으로 세척하여 상기 가교된 덱스트란 외부공간의 용액이 등장액이 되도록 맞추는 단계;상기 등장액으로 맞춰진 덱스트란 외부공간의 용액의 pH를 pH6~pH8로 맞추는 단계; 및점도조절제를 첨가하는 단계를 포함하는 피부 충전제 조성물 제조방법.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2794017A CA2794017C (en) | 2010-05-11 | 2011-03-07 | Dermal filler composition comprising cross-linked dextran having a molecular weight of 30,000 to 100,000 |
EP11780747.9A EP2570141B1 (en) | 2010-05-11 | 2011-03-07 | Dermal filler composition |
JP2013506062A JP2013524927A (ja) | 2010-05-11 | 2011-03-07 | 皮膚充填剤組成物 |
AU2011251138A AU2011251138B2 (en) | 2010-05-11 | 2011-03-07 | Dermal filler composition |
BR112012028232A BR112012028232B1 (pt) | 2010-05-11 | 2011-03-07 | composição de preenchedor dérmico |
US13/640,697 US9242030B2 (en) | 2010-05-11 | 2011-03-07 | Dermal filler composition |
RU2012146876/15A RU2012146876A (ru) | 2010-05-11 | 2011-03-07 | Композиция наполнителя для кожи |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0043753 | 2010-05-11 | ||
KR1020100043753A KR101003331B1 (ko) | 2010-05-11 | 2010-05-11 | 피부 충전제 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011142530A2 true WO2011142530A2 (ko) | 2011-11-17 |
WO2011142530A3 WO2011142530A3 (ko) | 2012-01-05 |
Family
ID=43513243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/001556 WO2011142530A2 (ko) | 2010-05-11 | 2011-03-07 | 피부 충전제 조성물 |
Country Status (11)
Country | Link |
---|---|
US (1) | US9242030B2 (ko) |
EP (1) | EP2570141B1 (ko) |
JP (1) | JP2013524927A (ko) |
KR (1) | KR101003331B1 (ko) |
CN (1) | CN102247618B (ko) |
AU (1) | AU2011251138B2 (ko) |
BR (1) | BR112012028232B1 (ko) |
CA (1) | CA2794017C (ko) |
HK (1) | HK1163562A1 (ko) |
RU (1) | RU2012146876A (ko) |
WO (1) | WO2011142530A2 (ko) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018203714A1 (en) * | 2017-03-09 | 2018-09-27 | Colin Campbell Marshall Moore | Improved Phalloplasty Method |
AU2017101856B4 (en) * | 2017-05-02 | 2021-08-05 | Oates & Family Pty Ltd | Procedure for Penile Girth Enhancement |
CN108653817B (zh) * | 2018-05-24 | 2021-02-02 | 上海其胜生物制剂有限公司 | 一种新型胶原刺激剂的制备方法 |
CN111558085A (zh) * | 2020-06-16 | 2020-08-21 | 红色未来科技(北京)有限公司 | 一种面部填充剂及其制备方法 |
KR102430642B1 (ko) * | 2020-07-03 | 2022-08-16 | 주식회사 메피온 | 필러 조성물 및 그 제조 방법 |
CN113041397A (zh) * | 2021-04-08 | 2021-06-29 | 红色未来科技(北京)有限公司 | 一种含有交联葡聚糖的面部填充剂及其制备方法 |
CN113244450A (zh) * | 2021-05-31 | 2021-08-13 | 美卓(杭州)医疗科技有限公司 | 一种用于手部抗衰的活性填充剂及其制备方法 |
CN114225117A (zh) * | 2021-11-08 | 2022-03-25 | 红色未来科技(北京)有限公司 | 一种含有交联葡聚糖的综合性面部填充剂及其制备方法 |
CN114146221A (zh) * | 2021-12-09 | 2022-03-08 | 杭州帕莱拉医疗科技有限公司 | 一种可注射右旋糖苷水凝胶微球填充剂及其制备方法 |
CN115252896A (zh) * | 2022-08-11 | 2022-11-01 | 成都恒美盛生物科技有限公司 | 一种面部填充剂生产用物料混合方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030233150A1 (en) | 2002-03-29 | 2003-12-18 | George Bourne | Tissue treatment |
KR100759091B1 (ko) | 2006-12-13 | 2007-09-17 | 조강선 | 피부 충전제 조성물 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04303445A (ja) * | 1991-03-29 | 1992-10-27 | Nippon Zeon Co Ltd | 創傷被覆材 |
US5605938A (en) | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
US5502042A (en) * | 1994-07-22 | 1996-03-26 | United States Surgical Corporation | Methods and compositions for treating wounds |
FR2764514B1 (fr) | 1997-06-13 | 1999-09-03 | Biopharmex Holding Sa | Implant injectable en sous-cutane ou intradermique a bioresorbabilite controlee pour la chirurgie reparatrice ou plastique et la dermatologie esthetique |
US6060461A (en) * | 1999-02-08 | 2000-05-09 | Drake; James Franklin | Topically applied clotting material |
US20040235791A1 (en) | 2002-01-25 | 2004-11-25 | Gruskin Elliott A. | Scar reduction |
CN1678277B (zh) * | 2002-07-29 | 2010-05-05 | 艾克里麦德公司 | 治疗皮肤病的方法和组合物 |
WO2006002050A1 (en) | 2004-06-15 | 2006-01-05 | Encore Therapeutics, Inc. | Phospholipid compositions and methods for their preparation and use |
SE0600091L (sv) | 2006-01-18 | 2007-04-17 | Bows Pharmaceuticals Ag | Förfarande för framställning av en dextranmatris för kontrollerad frisättning av insulin |
CN101209344B (zh) * | 2006-12-28 | 2012-07-04 | 赵超英 | 高渗液组合物在制备促进伤口愈合的药物中的应用 |
KR20090043973A (ko) * | 2007-10-30 | 2009-05-07 | 조강선 | 피부 충전제 조성물 |
-
2010
- 2010-05-11 KR KR1020100043753A patent/KR101003331B1/ko active IP Right Grant
-
2011
- 2011-03-07 JP JP2013506062A patent/JP2013524927A/ja active Pending
- 2011-03-07 BR BR112012028232A patent/BR112012028232B1/pt not_active IP Right Cessation
- 2011-03-07 CA CA2794017A patent/CA2794017C/en active Active
- 2011-03-07 EP EP11780747.9A patent/EP2570141B1/en active Active
- 2011-03-07 AU AU2011251138A patent/AU2011251138B2/en not_active Ceased
- 2011-03-07 WO PCT/KR2011/001556 patent/WO2011142530A2/ko active Application Filing
- 2011-03-07 RU RU2012146876/15A patent/RU2012146876A/ru unknown
- 2011-03-07 US US13/640,697 patent/US9242030B2/en active Active
- 2011-04-14 CN CN201110095861.9A patent/CN102247618B/zh active Active
-
2012
- 2012-05-03 HK HK12104352.0A patent/HK1163562A1/xx unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030233150A1 (en) | 2002-03-29 | 2003-12-18 | George Bourne | Tissue treatment |
KR100759091B1 (ko) | 2006-12-13 | 2007-09-17 | 조강선 | 피부 충전제 조성물 |
Non-Patent Citations (1)
Title |
---|
See also references of EP2570141A4 |
Also Published As
Publication number | Publication date |
---|---|
HK1163562A1 (en) | 2012-09-14 |
CA2794017A1 (en) | 2011-11-17 |
US20130053453A1 (en) | 2013-02-28 |
KR101003331B1 (ko) | 2010-12-23 |
AU2011251138A1 (en) | 2012-10-11 |
CA2794017C (en) | 2014-11-18 |
EP2570141A4 (en) | 2014-08-06 |
CN102247618A (zh) | 2011-11-23 |
WO2011142530A3 (ko) | 2012-01-05 |
BR112012028232B1 (pt) | 2018-09-04 |
EP2570141A2 (en) | 2013-03-20 |
US9242030B2 (en) | 2016-01-26 |
EP2570141B1 (en) | 2018-07-25 |
JP2013524927A (ja) | 2013-06-20 |
CN102247618B (zh) | 2014-06-18 |
RU2012146876A (ru) | 2014-06-20 |
AU2011251138B2 (en) | 2013-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011142530A2 (ko) | 피부 충전제 조성물 | |
KR100759091B1 (ko) | 피부 충전제 조성물 | |
Duranti et al. | Injectable hyaluronic acid gel for soft tissue augmentation: A clinical and histological study | |
EP2421551B1 (en) | Silk fibroin hydrogels and uses thereof | |
RU2648450C2 (ru) | Приемлемая для инъекций стерильная водная композиция на основе сшитой гиалуроновой кислоты и гидроксиапатита для применения в пластической хирургии | |
AU2004261752B2 (en) | Complex matrix for biomedical use | |
US20110111031A1 (en) | Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof | |
US20110052695A1 (en) | Drug delivery platforms comprising silk fibroin hydrogels and uses thereof | |
HUE031598T2 (hu) | Érzéstelenítõ szereket tartalmazó hialuronsav alapú gélek | |
US20110189292A1 (en) | Dermal fillers comprising silk fibroin hydrogels and uses thereof | |
Wang et al. | Intraarticularly injectable silk hydrogel microspheres with enhanced mechanical and structural stability to attenuate osteoarthritis | |
CN113549227A (zh) | 化学交联水凝胶及其微球、制备方法与应用 | |
Orasugh et al. | Utilization of cellulose nanocrystals (CNC) biopolymer nanocomposites in ophthalmic drug delivery system (ODDS) | |
CN115605270A (zh) | 物理混合ha-胶原蛋白皮肤填充物 | |
KR20090043973A (ko) | 피부 충전제 조성물 | |
EP3199184A1 (en) | Matrix for restoring soft tissue and producing method therefor | |
KR101005287B1 (ko) | 공막돌륭술 밴드 및 이의 제조 방법 | |
KR20090068088A (ko) | 새로운 피부 충전제 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11780747 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011251138 Country of ref document: AU Ref document number: 8172/DELNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2794017 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2011251138 Country of ref document: AU Date of ref document: 20110307 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13640697 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011780747 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013506062 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12012502113 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1201005694 Country of ref document: TH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2012146876 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012028232 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012028232 Country of ref document: BR Kind code of ref document: A2 Effective date: 20121105 |